abstract |
The present invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and their use for the treatment of any disease or condition associated with elevated PAI-1. The present invention includes, but is not limited to, the use of these compounds for preventing or reducing thrombus formation and fibrosis, promoting thrombus lysis, and modulating lipid metabolism and treating diseases or conditions associated with elevated levels of PAI-1, cholesterol, or lipids. |